BridgeBio Oncology Therapeutics opened lower at $2.50, compared with its previous close of $2.56. In the last trading session, the stock traded between $2.00 and $2.68. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in BridgeBio Oncology Therapeutics is now worth
$ 24.70
Resulting in a loss of
$ 75.30 (75.30%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.18 (-6.88%)
Day High
$2.68
Day Low
$2.00
Day Open
$2.50
Prev Close
$2.56
Volume
6,82,623
1W Return
3.70%
1M Return
-26.56%
3M Return
-74.11%
6M Return
-69.78%
1Y Return
-81.30%
Fundamentals
Market Cap ($ Mn)
191
PE Ratio
-
PB Ratio
2.17
PEG Ratio
-
ROE
-266.60%
ROCE
-57.83%
EPS (TTM)
-
Investment Returns
1 Week
3.70%
1 Month
-26.56%
3 Months
-74.11%
6 Months
-69.78%
9 Months
-80.20%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Piper Sandler lowers BridgeBio Oncology price target to $15
Piper Sandler lowered BridgeBio Oncology's price target from $21 to $15. Analyst Biren Amin maintained an Overweight rating on the stock. The price target reduction amounts to a $6 decrease.
Yesterday
11Nov
Wedbush lowers BridgeBio Oncology price target to $9, keeps Outperform
Wedbush lowers BridgeBio Oncology price target from $25 to $9. Analyst David Nierengarten maintains Outperform rating. Price target reduction marks a $16 decrease in valuation.
Yesterday
11Nov
BridgeBio Oncology Q3FY26 Results: Loss narrows to $34.2M, EPS beats estimate
Net loss narrowed to $34.2 million in Q3 2026 from $44.8 million in Q3 2025. EPS of $(0.43) beat analyst consensus estimate of $(0.69) by 37.68%. R&D expenses declined to $29.6 million due to reduced clinical program spending. Cash position stands at $315.3 million, providing operational runway into 2029.
2 days ago
21Oct
Morgan Stanley lowers BridgeBio Oncology price target to $13
Morgan Stanley lowered BridgeBio Oncology's price target from $18 to $13. Analyst Sean Laaman maintained an Overweight rating on the stock. The revision represents a $5 reduction in the estimated value per share.
22 days ago
20Oct
Oppenheimer maintains Outperform on BridgeBio, cuts target to $16
Oppenheimer maintained an Outperform rating on BridgeBio Oncology. Price target lowered from $22 to $16 by analyst Mazahir Alimohamed. The rating action reflects a $6 reduction in the estimated value.
23 days ago
13Oct
BridgeBio Oncology grants 90,000 stock options to new hire
BridgeBio Oncology granted 90,000 stock options to a new employee hired in September 2026. Exercise price set at $3.31 per share based on Nasdaq closing price. Awards issued under the 2025 Inducement Plan outside shareholder-approved pools. Vesting occurs over four years with a one-year cliff followed by monthly installments.
